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Abstract
Background: Several studies have noted the significance of measuring anti-cyclic citrullinated peptide (CCP)
antibodies in juvenile idiopathic arthritis (JIA) as an important indicator for destructive disease, as is the case in
rheumatoid arthritis (RA). While the role of anti-CCP antibodies in RA and JIA has become better understood, the
identity of the target proteins of this modification has remained elusive. In this study, we evaluated serum from
patients with various subtypes of JIA to investigate the presence of anti-deiminated (citrullinated) fibrinogen and
anti-citrullinated a-enolase antibodies, and their association with RF and anti-CCP antibody isotypes.
Methods: Sera were obtained from 96 JIA patients, 19 systemic lupus erythematosus (SLE) patients, and 10 healthy
children. All sera were measured for antibodies against citrullinated and native fibrinogen and a-enolase by an
enzyme linked immunosorbent assay (ELISA). In addition, all sera were assayed for anti-CCP antibody isotypes and
rheumatoid factor (RF) isotypes by ELISA. The relationship between anti-citrullinated fibrinogen and anti-a-enolase
antibodies and disease activity and joint damage were also investigated. All results were correlated with clinical
and laboratory parameters using Spearman’s rho correlation coefficient. Multiple logistic regression analysis was
utilized to identify which variables were associated with joint erosions and diagnosis of JIA.
Results: Thirty-one JIA patients (32%) demonstrated reactivity to citrullinated fibrinogen and 9 (9%) to citrullinated
a-enolase. Reactivity to citrullinated fibrinogen and a-enolase was predominantly found in IgM RF-positive
polyarthritis patients. Fourteen JIA patients reacted with native a-enolase and a higher percentage of SLE patients
reacted with citrullinated a-enolase when compared to JIA patients. Anti-citrullinated fibrinogen antibodies
correlated with the presence of IgG anti-CCP antibodies and IgA and IgM RF. The presence of anti-citrullinated
a-enolase antibodies correlated with IgA anti-CCP antibodies. IgG anti-CCP antibodies were significantly associated
with joint damage and anti-citrullinated fibrinogen antibodies were strongly associated with JIA when compared to
control groups. Anti-citrullinated fibrinogen antibodies demonstrated high sensitivity (81%) for IgM RF-positive
polyarticular JIA. IgG anti-CCP antibodies had the highest specificity (95%) for JIA, with anti-citrullinated fibrinogen
antibodies, IgA anti-CCP antibodies and IgA RF all following at 84%.
Conclusions: JIA patient sera exhibited strong reactivity to anti-citrullinated fibrinogen antibodies and
demonstrated high sensitivity and specificity for JIA, primarily in IgM RF-positive polyarthritis patients. Fibrinogen is
one of several protein targets for citrullination in JIA.
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Anti-cyclic citrullinated peptide (anti-CCP) antibodies
have been established as an important diagnostic tool in
rheumatoid arthritis (RA), especially being demonstrated
in patients with a more aggressive disease course [1].
The role of anti-CCP antibodies in juvenile idiopathic
arthritis (JIA) remains undefined [2]. It has been shown
that anti-CCP antibodies are less prevalent in JIA popu-
lations, mainly restricted to polyarthritis patients or
patients with joint damage [3-6]. Several studies have
noted the significance of measuring anti-CCP antibodies
in JIA as an important indicator for destructive disease,
as is the case in RA [3-9]. Recently, the identity of var-
ious immunoglobulin isotypes of anti-CCP antibodies
has also been reported in RA [10] and JIA [11]. These
studies revealed that a varied pattern of isotype usage
early in disease was possibly associated with aggressive
disease, especially when all three isotypes (IgG, IgA, and
IgM) were present [2,10,11].
While the role of anti-CCP antibodies in RA and JIA
has become better understood, the identity of the target
proteins of this modification has remained elusive. Snir
et al. [12] evaluated antibody reactivities to citrullinated
proteins in RA patients to determine their prevalence
a n ds i g n i f i c a n c e .T h e yf o u n dt h a tR Ap a t i e n t sd e m o n -
strated varying antibody reactivities to citrullinated fibri-
nogen, citrullinated a-enolase, and the C1 epitope of
citrullinated type II collagen (citC1
III). Other studies
have examined the significance of citrullinated fibrino-
gen [13-19], citrullinated a-enolase [13,20,21], citC1
III
[13,22-24], and citrullinated vimentin [13,25-30] in RA
and experimental arthritis. To date, only two studies on
citrullinated vimentin has documented the identity and
evaluated the significance of citrullinated proteins in a
JIA population [31,32].
In this study, we evaluated serum from patients with
various subtypes of JIA to investigate the presence of
anti-deiminated (citrullinated) fibrinogen and anti-citrul-
linated a-enolase antibodies, and their association with
RF and anti-CCP antibody isotypes. The aim of this
study was to determine the prevalence and significance
of previously identified target proteins for citrullination
and elucidate their role in the disease process of JIA.
Findings from this study point to fibrinogen as a target
of citrullination in IgM RF-positive polyarticular JIA
patients.
Materials and methods
Serum Samples
Sera were obtained from the Saint Louis University
Pediatric Rheumatology Division outpatient clinics at
the Saint Louis University Medical Center and Cardinal
Glennon Children’s Medical Center following informed
consent. Sera were stored at -80°C until assayed. A total
of 96 individual JIA serum samples (77 female and 19
male) were collected consecutively, including 16 with
IgM RF-positive polyarthritis, 36 with IgM RF-negative
polyarthritis, 25 with oligoarthritis, 13 with systemic-
onset arthritis, 3 with psoriatic arthritis, and 3 with
enthesitis-related arthritis. The JIA patients had a mean
age of 11.2 ± 5.9 years, and mean disease duration of
3.9 ± 4.4 years (Table 1). In the JIA population, 88
patients (91.7%) were Caucasian, 3 (3.1%) were African
American, 2 (2.1%) were Hispanic, and 3 (3.1%) were
classified as other races. The patient demographics
depict an accurate representation of the JIA population
at our Pediatric Rheumatology outpatient clinics. Sixty-
seven of the JIA patients had active disease at the time
of sample collection, compared to 29 who were in dis-
ease remission. Radiographic joint damage was noted in
20 of 96 JIA patients. All JIA patients in this study ful-
filled the International League of Associations of Rheu-
matology criteria [33,34].
Sera from 19 patients with pediatric-onset systemic
lupus erythematosus (SLE) (17 female and 2 male) were
collected consecutively from the outpatient clinics, fol-
lowing informed consent. The mean age of the SLE
patients was 15.7 ± 3.1 years and the mean disease dura-
tion was 2.7 ± 3.2 years. Fifteen SLE patient (78.9%)
were Caucasian, 2 (10.5%) were African American, 1
(5.3%) was Hispanic, and 1 (5.6%) was Filipino. Sera
were also collected consecutively from 10 healthy chil-
dren (9 female and 1 male) at the well-child clinic at
Cardinal Glennon Children’s Medical Center following
informed consent. The mean age for the healthy chil-
dren was 14.0 ± 5.9 years. Six healthy children (60.0%)
were Caucasian, 2 (20.0%) were African American, and
2 were Asian (20.0%). The study was approved by the
Institutional Review Board of the Saint Louis University
Medical Center.
Laboratory and clinical evaluation
Erythrocyte sedimentation rate (ESR) was determined by
the modified Westergren technique and considered
Table 1 Demographic and laboratory features of JIA
patients (n = 96)
Sex, no. females/males 77/19
Age, mean ± SD years (range) 11.2 ± 5.9 (2-17)
Disease Duration, mean ± SD years (range) 3.9 ± 4.4 (onset-16)
Tender/Swollen joint count, mean ± SD (range) 7.3 ± 5.8 (0-24)
No. patients with joint damage (%) 20 (20.8)
CRP, mean ± SD mg/dL (% positive) 1.56 ± 1.96 (39.3)
ESR, mean ± SD mm/hr (% positive) 27.13 ± 29.32 (52.1)
CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.
Cut-points for a positive value: CRP (≥0.8 mg/dl), ESR (≥20 mm/hr).
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determined by electroimmunoassay and a value of ≥0.8
mg/dl was considered elevated. Mean levels of ESR and
CRP are shown in Table 1. Initial determination of IgM
RF positivity was performed by nephelometry or latex
agglutination, which is how patients were classified for
seropositive JIA. The QUANTA Lite RF enzyme-linked
immunosorbent assays (ELISA) (Inova Diagnostics, Inc.,
San Diego, CA) were used for the detection of IgA and
IgM RF according to the manufacturer’s instructions.
The cut-off value for positive IgA or IgM RF was 6 U. A
third generation anti-CCP antibody test, the QUANTA
Lite CCP3 ELISA (Inova Diagnostics, Inc., San Diego,
CA), was used for the detection of IgG anti-CCP antibo-
dies according to the manufacturer’s instructions. The
cut-off value for a positive result was 20 U. IgA and
IgM anti-CCP antibodies were measured by ELISA
(QUANTA Lite CCP3 ELISA, Inova Diagnostics, San
Diego, CA) as previously described [11]. Cut-off values
for a positive result were calculated at optical density
(OD) = 0.16 and OD = 0.43, respectively, determined as
the mean plus two standard deviations (SD) of a healthy
population from a previous study [11]. Clinical data
regarding signs of active disease (including joint pain
and swelling, limitations of range of motion, fever, rash,
visceral involvement, and inflammatory markers) were
collected from patient records of the Pediatric Rheuma-
tology clinics. Radiological data was evaluated for signs
of joint damage (defined as joint space narrowing
and/or erosions) by musculoskeletal radiologists and
reviewed by the Pediatric Rheumatologists. Both clinical
data and radiological data were collected from the same
time period as serum was collected.
In vitro deimination of human fibrinogen
Deimination of fibrinogen was performed as previously
described [15,16]. Briefly, plasminogen-depleted human
fibrinogen (95% pure, Calbiochem, Meudon, France)
was purified by affinity chromatography on a protein-G
column (HiTrap protein G, GE Healthcare, Piscataway,
New Jersey) according to the manufacturer’si n s t r u c -
tions. Deimination was then performed using rabbit ske-
letal muscle peptidyl arginine deiminase (PAD) (Sigma,
St. Louis, Missouri, USA, 7 U/mg fibrinogen) in 0.1 M
Tris-HCl (pH 7.4), 10 mM CaCl2, 5 mM dithiothreitol
for 2 hours at 37°C.
Citrullinated and native fibrinogen ELISAs
ELISAs with citrullinated and native forms of fibrinogen
were performed as previously described [15,16] with
some modifications. Briefly, ninety-six-well microtitre
plates (Nunc, Roskilde, Denmark) were coated with
human native fibrinogen or human citrullinated fibrino-
gen (5 μg/ml) diluted in phosphate buffered saline (PBS)
and incubated overnight at 4°C. The plates were then
blocked with PBS containing 2% bovine serum albumin
(BSA) (Sigma, St. Louis, Missouri, USA) for one hour at
4°C, followed by 3 washes with PBS/0.05% Tween.
Patient sera, diluted 1:50 in 2 M NaCl PBS, were added
to the wells in duplicate and incubated for one hour at
room temperature (RT) with gentle agitation. After 3
washes with PBS/0.05% Tween, horseradish peroxidase
(HRP)-labeled goat anti-human IgG (g-chain specific)
(Antibodies Incorporated, Davis, California, USA)
diluted 1:15,000 was added to the wells and incubated
for one hour at RT. After 3 washes with PBS/0.05%
Tween, the amount of antibodies bound were detected
with tetramethylbenzidine (TMB), an HRP substrate
(BioFX, Owing Mills, Maryland, USA), and 0.25 M
H2SO4 was used to stop the reaction. The OD was read
at 450 nm (Tecan Group Ltd., Männedorf, Switzerland).
Patient results from the duplicate wells were averaged
and the OD from a blank well containing PBS/0.05%
Tween was subtracted from the average. Serum was
considered positive if the titer reached 2 SD above the
mean for healthy controls. Positive cut-off points were
OD = 0.59 for anti-citrullinated fibrinogen antibodies
and OD = 0.46 for native fibrinogen.
Citrullinated and native a-enolase ELISAs
Citrullinated and native a-enolase ELISAs were per-
formed as previously described by Lundberg et al. [21]
with some modifications. Briefly, 96-well microtitre
plates (Nunc, Roskilde, Denmark) were coated with
either a citrullinated a-enolase peptide (CKIHA-X-
EIFDS-X-GNPTVEC, where X represents citrulline) or
the arginine-containing control peptide (CKIHAR-
EIFDSRGNPTVEC) (Bachem Americas Inc., Torrance,
California, USA) at 5 μg/ml diluted in 50 mM carbonate
buffer (pH 9.6) and incubated overnight at 4°C. Follow-
ing 3 washes with PBS/0.1% Tween, the plates were
blocked with 2% BSA diluted in PBS for one hour at
RT. The plates were washed as described above. Serum
samples were diluted 1:50 in radioimmunoassay (RIA)
buffer (10 mM Tris, 1% BSA, 350 mM NaCl, 1% Triton-
X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS)), added in duplicate, and incubated for
90 minutes at RT with gentle agitation. After 3 washes
with PBS/0.1% Tween, the plates were incubated for one
hour at RT with gentle agitation with HRP-conjugated
goat anti-human IgG (g-chain specific) (Antibodies
Incorporated, Davis, California, USA), diluted 1:10,000
in RIA buffer. After a final wash step, bound antibodies
were detected with TMB and the reaction was stopped
by the addition of 0.25 M H2SO4. The absorbance was
measured at 450 nm using a Tecan plate reader (Tecan
Group Ltd., Männedorf, Switzerland). Patient results
from the duplicate wells were averaged and the OD
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subtracted from the average. Serum was considered
positive if the titer reached 2 SD above the mean for
healthy controls. Cut-off values were considered positive
at OD = 0.91 for anti-citrullinated a-enolase antibodies
and OD = 0.55 for native a-enolase.
Statistical Analyses
Patient groups were compared using Student’s t test
and c
2 test for proportions. For tables with cells with
small frequencies, Fisher’s exact test was used. Com-
parisons between JIA subtypes and control groups
were performed with one-way ANOVA followed by
Bonferroni post hoc analysis. Correlations were ana-
lyzed using Spearman’s rho correlation coefficient.
Multiple logistic regression analysis was utilized to
identify which variables were associated with joint ero-
sions and diagnosis of JIA. Variables associated with
joint damage and JIA in univariate analysis were
included in regression analysis. Results were expressed
as odds ratios (OR) with 95% confidence intervals (CI)
and p-values. The sensitivity, specificity, and positive
predictive value (PPV) of citrullinated fibrinogen,
citrullinated a-enolase, anti-CCP antibody isotypes,
and RF isotypes were calculated in the JIA population.
The sensitivity expresses the percentage of JIA patients
positive for the test and specificity expresses the fre-
quency of negative tests in the absence of JIA or JIA
subtypes. PPV describes the group of patients with a
positive test result who are correctly diagnosed. Statis-
tical analyses were carried out using SPSS version 15.0
( C h i c a g o ,I L ,U S A ) .Ap - v a l u e<0 . 0 5w a sc o n s i d e r e d
statistically significant.
Results
JIA serum reactivity to native and citrullinated fibrinogen
and a-enolase
Thirty-one JIA patients (32.3%) showed reactivity to
citrullinated fibrinogen (Table 2). IgM RF-positive poly-
arthritis patients demonstrated the highest level of reac-
tivity with citrullinated fibrinogen (Table 2), which was
significantly higher than other JIA subtypes and healthy
and SLE control groups (Table 3). Seven of the 11
(63.6%) IgM RF-negative polyarthritis patients who were
positive for anti-citrullinated fibrinogen antibodies were
also positive for IgM RF by ELISA. Anti-citrullinated
fibrinogen antibodies were significantly elevated in JIA
patients when compared to SLE and healthy children
(Figure 1A). Seven (7.3%) JIA patients reacted with
native fibrinogen, including one with IgM RF-positive
polyarthritis, 3 with IgM RF-negative polyarthritis, and 3
with oligoarthritis.
Nine (9.4%) JIA patients showed reactivity to citrulli-
nated a-enolase (Table 2). SLE patients exhibited
significantly higher reactivity with citrullinated a-enolase
in comparison to JIA and healthy children (Figure 1B).
Fourteen (14.6%) JIA patients reacted with native a-
enolase, including 1 with IgM RF-positive polyarthritis,
9 with IgM RF-negative polyarthritis, 2 with oligoarthri-
tis, and 2 with enthesitis-related arthritis.
Five JIA patients reacted with both citrullinated fibri-
nogen and citrullinated a-enolase, including 3 with IgM
RF-positive polyarthritis, one with IgM RF-negative
polyarthritis, and one with systemic-onset JIA. All 3
IgM RF-positive JIA patients had active disease, with
elevated ESR. Additionally, 2/3 IgM RF-positive polyar-
thritis patients were positive for IgA RF and anti-CCP
antibody isotypes. The patient with systemic-onset JIA
had active disease, high ESR, and macrophage activation
syndrome in the past and now manifested purely polyar-
ticular disease. The IgM RF-negative polyarthritis
patient was asymptomatic at the time of sample collec-
tion, but still demonstrated elevated levels of IgA and
IgG anti-CCP antibodies.
Commonality between anti-citrullinated antibody
reactivities in JIA
Antibodies against various citrullinated proteins may be
present in JIA sera at the same time. Figure 2 illustrates
the antibody reactivity pattern in this JIA cohort. The
prominent subgroup in JIA included patients who
reacted only with citrullinated fibrinogen (17%). Ninety-
three percent of JIA patients positive for IgG anti-CCP
antibodies also reacted with citrullinated fibrinogen,
making up 10% of the JIA population (Figure 2). Three
(3%) IgM RF-positive polyarthritis patients were positive
for IgG anti-CCP antibodies and both anti-citrullinated
fibrinogen and a-enolase antibodies (Figure 2).
Clinical and serological correlations
Anti-citrullinated fibrinogen antibodies correlated sig-
nificantly with anti-citrullinated a-enolase antibody
levels (r = 0.35, p = 0.001), IgG anti-CCP antibodies (r
= 0.55, p = 0.001), and IgA and IgM RF (r = 0.40 and
r = 0.52, respectively; p = 0.001). No significant corre-
lations were noted with anti-citrullinated fibrinogen
antibodies and disease duration, patient age, joint
d a m a g e ,d i s e a s ea c t i v i t y ,E S R ,o rC R P .A n t i - c i t r u l l i -
nated a-enolase antibodies levels correlated signifi-
cantly with IgA anti-CCP antibodies (r = 0.31, p =
0.007) in JIA. Additionally, a correlation between
patient age and anti-citrullinated a-enolase antibodies
were also noted (r = 0.30, p = 0.001). No significant
correlations were found between anti-citrullinated a-
enolase antibodies and disease duration, joint damage,
disease activity, ESR, or CRP. Similar evaluation with
native fibrinogen and native a-enolase yielded no sta-
tistically significant results.
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IgA and IgM RF were all significantly elevated in
patients with a positive result for anti-citrullinated fibri-
nogen antibodies versus patients who were negative for
anti-citrullinated fibrinogen antibodies (Table 4).
Relationship between serological markers and disease
course
Mean levels of IgG anti-CCP antibodies and IgM RF
were significantly elevated in JIA patients with joint
damage (60.6U and 37.0U, respectively) compared
to those with no joint damage (15.2U and 14.7U, respec-
tively) (p < 0.05). IgA anti-CCP antibodies, IgA RF, and
anti-citrullinated fibrinogen antibodies were also elevated
in patients with joint damage, but did not reach statistical
significance. IgG anti-CCP antibodies, IgA anti-CCP anti-
bodies, IgA RF, IgM RF, and anti-citrullinated fibrinogen
antibodies were included in logistic regression analysis.
Regression analysis showed that IgG anti-CCP antibodies
(OR = 5.3 [95% CI 1.6-17.7] p = 0.007) were the indepen-
dent factor associated with joint damage in JIA.
When evaluating disease activity, mean levels of CRP
and ESR were significantly elevated in patients with
active disease (p < 0.01) and both were included in
regression analysis. ESR (OR = 3.2 [95% CI 1.4-7.3] p =
0.006) was the independent factor associated with active
disease in this JIA cohort. No significant differences
were observed between anti-citrullinated fibrinogen
Table 2 Antibody concentration and positivity in JIA subtypes (n = 96)
Poly RF+
n=1 6
Mean ± SD
Poly RF-
n = 36 Mean
±S D
Oligo
n = 25 Mean
±S D
Systemic
n = 13 Mean
±S D
Enthesitis
n=3
Mean
Psoriatic
n=3
Mean
Citrullinated Fibrinogen (OD)
Positivity n(%)
1.6 ± 1.1
13 (81.3%)
0.60 ± 0.75
11(30.6%)
0.54 ± 0.65
6(24.0%)
0.36 ± 0.18
1(7.7%)
0.37
0(0%)
0.28
0(0%)
Citrullinated a-Enolase (OD)
Positivity n(%)
0.54 ± 0.49
3(18.8%)
0.47 ± 0.51
2(5.6%)
0.35 ± 0.16
0(0%)
0.40 ± 0.24
1(7.7%)
1.6
2(66.7%)
1.2
1(33.3%)
IgG CCP (U)
Positivity n(%)
109.9 ± 116.4
9(56.3%)
18.3 ± 63.96
5(13.9%)
0.76 ± 12.7
0(0%)
4.5 ± 11.4
0(0%)
3.7
0(0%)
1.6
0(0%)
IgA CCP (OD)
Positivity n(%)
0.28 ± 0.56
4(25.0%)
0.11 ± 0.21
6(16.7%)
0.04 ± 0.02
0(0%)
0.04 ± 0.04
0(0%)
0.09
0(0%)
0.04
0(0%)
IgM CCP (OD)
Positivity n(%)
0.91 ± 1.2
5(31.3%)
0.53 ± 0.77
10(27.8%)
0.17 ± 0.09
0(0%)
0.20 ± 0.12
1(7.7%)
0.13
0(0%)
0.31
0(0%)
IgA RF (U)
Positivity n(%)
19.4 ± 29.8
10(62.5%)
1.7 ± 4.5
4(11.1%)
1.1 ± 2.4
0(0%)
0.99 ± 3.4
1(7.7%)
2.1
0(0%)
0.15
0(0%)
IgM RF (U)
Positivity n(%)
66.3 ± 52.4
16(100%)
14.8 ± 23.5
17(47.2%)
3.6 ± 11.0
5(20.0%)
15.2 ± 18.1
8(61.5%)
3.3
0(0%)
2.9
0(0%)
Continuous variables are expressed as means ± SD. Anti-CCP antibodies: anti-cyclic citrullinated peptide antibodies; CRP: C-reactive protein; ESR: erythrocyte
sedimentation rate; n: number of patients; OD: optical density; RF: rheumatoid factor; U: Units. Cut points for positive values: Anti-citrullinated fibrinogen
antibodies (OD≥0.59), Anti-citrullinated a-enolase antibodies (OD≥0.91), IgG anti-CCP antibodies (≥20U), IgA anti-CCP antibodies (OD≥0.16), IgM anti-CCP
antibodies (OD≥0.43), IgA RF (≥6U), IgM RF (≥6U).
Table 3 Significant differences in anti-citrullinated
fibrinogen antibody levels in JIA subtypes and healthy
and SLE control groups
Study Group JIA subtypes and
Control Groups
Citrullinated-
Fibrinogen p-value
IgM RF-positive
polyarthritis
IgM RF-negative
polyarthritis
0.002
Oligoarthritis 0.001
Systemic-onset arthritis < 0.001
Psoriatic arthritis 0.049
Enthesitis-related arthritis 0.049
Healthy 0.001
SLE < 0.001
Bonferroni post hoc analysis of association between anti-citrullinated
fibrinogen levels in JIA subtypes and control groups. Significant differences at
p < 0.05. JIA: juvenile idiopathic arthritis; RF: rheumatoid factor; SLE: systemic
lupus erythematosus.
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when assessing disease activity in JIA.
Significantly elevated mean levels IgG anti-CCP antibo-
dies and anti-citrullinated fibrinogen antibodies were
observed in JIA patients compared to the control patient
groups (SLE and healthy combined) (p < 0.05). As pre-
viously indicated, mean anti-citrullinated a-enolase anti-
body levels were significantly elevated in the control
group, mainly SLE patients, compared to the JIA popula-
tion (p < 0.05). When including IgG anti-CCP antibodies,
Figure 1 Levels of anti-citrullinated fibrinogen and g-enolase antibodies in JIA, SLE, and healthy children. IgG antibody recognition of
citrullinated fibrinogen (a) and citrullinated a-enolase (b) by ELISA in sera from JIA patients (n = 96), SLE patients (n = 19), and healthy children
(n = 10). Bars indicate the median levels of citrullinated antibodies in each group. P-values were considered statistically significant at < 0.05. OD:
optical density.
Figure 2 Patterns of citrullinated antibody reactivity in JIA sera (n = 96). Cit-Eno: anti-citrullinated a-enolase antibodies; Cit-fib: anti-
citrullinated fibrinogen antibodies; IgG CCP: IgG anti-cyclic citrullinated peptide antibodies.
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nated a-enolase antibodies in multiple logistic regression
analysis, anti-citrullinated fibrinogen antibodies were sig-
nificantly correlated with JIA (OR = 14.8 [95% CI 1.4-
160.9] p = 0.027), while anti-citrullinated a-enolase anti-
bodies demonstrated an inverse relationship with JIA (OR
= 0.29 [95% CI 0.13-0.64] p = 0.002).
Sensitivity and specificity of anti-citrullinated fibrinogen
and a-enolase antibodies for JIA
The sensitivity, specificity, and PPV of anti-citrullinated
fibrinogen antibodies, anti-citrullinated a-enolase antibo-
dies, IgG and IgA anti-CCP antibodies, and IgA and IgM
RF for JIA subtypes are shown in Table 5. Sensitivities,
specificities and PPVs were calculated for the overall JIA
population and for each subtype, excluding enthesitis-
related JIA and psoriatic JIA due to small sample size.
Overall sensitivities ranged from 9.4% to 47.9% and speci-
ficities from 57.9% to 94.7%. IgM RF and anti-citrullinated
fibrinogen antibodies demonstrated the strongest sensitiv-
ity for JIA overall (47.9% and 32.3%, respectively). Anti-
citrullinated fibrinogen antibodies demonstrated high sen-
sitivity for IgM RF-positive polyarthritis at 81.3%. IgG and
IgA anti-CCP antibodies (94.7% and 84.2%, respectively),
anti-citrullinated fibrinogen antibodies (84.2%), and IgA
RF (84.2%) exhibited the highest specificity for JIA. IgG
anti-CCP antibodies and anti-citrullinated fibrinogen anti-
bodies demonstrated the highest PPV for JIA overall and
IgG anti-CCP antibodies and IgA RF in IgM RF-positive
polyarticular JIA (Table 5).
Discussion
Several studies in RA and JIA have evaluated the poten-
tial role of anti-CCP antibodies in disease pathogenesis
[1,2]. Recent studies in RA have attempted to identify
the target proteins for citrullination [12]. In RA, fibrino-
gen has been identified as one of the protein targets for
this modification and a potential marker of disease and
predictor of radiographic progression [14,17]. We
observed elevated levels of anti-citrullinated fibrinogen
antibodies in 31/96 (32%) of the JIA population, most
commonly in IgM RF-positive polyarthritis patients
(81%). The prevalence of anti-citrullinated fibrinogen
antibodies within the IgM RF-positive polyarthritis sub-
type was similar to findings in RA, with ranges from
48% to 82% [12,18,19]. Moreover, the significant rela-
tionship between IgG anti-CCP antibodies and IgM RF
with anti-citrullinated fibrinogen antibodies has been
shown in adult RA [12-14], similar to what we have
documented in our cohort of IgM RF-positive polyarticu-
lar JIA patients. Varying serological patterns of reactivity
were noted in JIA, with the most frequent combination
being IgG anti-CCP antibodies and anti-citrullinated fibri-
nogen antibodies, or anti-citrullinated fibrinogen antibo-
dies alone. Similar findings have been reported in RA
[12]. This again adds credence that the IgM RF-positive
polyarticular JIA onset-type patients are similar to adult
RA and the potential for life long disease.
Previous studies have shown association between a-
enolase and various autoimmune diseases, including SLE,
systemic sclerosis, Behçet’s disease, mixed cryoglobuline-
mia, autoimmune hepatitis, and primary sclerosing cho-
langitis [35-37]. Anti-a-enolase antibodies have also been
associated with renal involvement in SLE [35]. This docu-
mentation of a-enolase in various autoimmune diseases
may also explain the high prevalence of native a-enolase
in the JIA population. Further evaluation is required to
determine the significance of citrullinated and native a-
enolase in the SLE and JIA populations.
There were some limitations to our current study. The
size of the healthy population was small and the control
groups and JIA patients were not precisely matched by
age or gender. Though the group of healthy children
was small, the cut-off values generated from this group
provided a range of results similar to previous studies in
RA [12,18,19]. While the present results indicate mea-
surement of anti-citrullinated fibrinogen antibodies as a
potential marker for identifying patients with more
aggressive disease, such as those with IgM RF-positive
polyarthritis, longitudinal studies with early-onset JIA
patients are necessary to further verify this claim.
Measurement of all 3 anti-CCP antibody isotypes has
been suggested in both RA [10] and JIA [11]. Verpoort
et al. [10] found that undifferentiated arthritis patients
who were positive for both IgA and IgM anti-CCP anti-
bodies were more likely to develop RA than those with
IgG anti-CCP antibodies alone. We previously noted
that the presence of all 3 anti-CCP antibody isotypes in
Table 4 Significant differences in antibody levels in JIA
patients positive versus negative for anti-citrullinated
fibrinogen antibodies
Positive for
Anti-Citrullinated
Fibrinogen
Antibodies
n=3 1
Negative for
Anti-Citrullinated
Fibrinogen
Antibodies
n=6 5
P-Value
IgM RF (U) 42.86 6.59 < 0.001
IgA RF (U) 15.27 1.25 0.005
IgG anti-CCP
Antibodies (U)
65.64 0.86 0.001
IgA anti-CCP
Antibodies (OD)
0.22 0.05 0.026
IgM anti-CCP
Antibodies (OD)
0.69 0.32 0.009
Anti-CCP antibodies: anti-cyclic citrullinated peptide antibodies; n = number of
patients; OD = optical density; RF = rheumatoid factor; U: Units. Cut points for
positive values: Anti-citrullinated fibrinogen antibodies (OD≥0.59), IgG anti-
CCP antibodies (≥20U), IgA anti-CCP antibodies (OD≥0.16), IgM anti-CCP
antibodies (OD≥0.43), IgA RF (≥6U), IgM RF (≥6U). P-value < 0.05 was
considered statistically significant.
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The present study demonstrated strong specificities for
IgG and IgA anti-CCP antibodies in the overall JIA
population, in addition to high specificities in the poly-
articular JIA patients. This data further supports
measuring anti-CCP antibody isotypes in JIA patients,
particular those patients with polyarticular disease. Mea-
suring IgM RF by ELISA has been shown to be a more
sensitive method of measurement than latex agglutina-
tion or nephelometry [2]. In agreement with several
Table 5 Sensitivity, Specificity, and PPV of anti-citrullinated antibodies and RF isotypes for the overall JIA population
and JIA subtypes
Sensitivity (%)
With 95%CI
Specificity (%)
With 95% CI
PPV (%)
With 95% CI
Anti-Citrullinated Fibrinogen Antibodies (> 0.59OD)
Overall 32.3 (23.3-42.7) 84.2 (59.5-95.8) 91.2 (75.2-97.7)
Poly RF-positive 81.3 (53.7-95.0) 78.8 (69.2-86.1) 38.2 (22.7-56.4)
Poly RF-negative 30.6 (16.9-48.3) 70.9 (59.4-80.3) 32.4 (18.0-50.6)
Oligoarthritis 24.0 (10.2-45.5) 68.9 (58.1-78.0) 17.6 (7.4-35.0)
Systemic-Onset 7.7 (0.4-37.9) 67.6 (57.6-76.4) 29.4 (0.1-17.1)
Anti-Citrullinated a-Enolase Antibodies (> 0.91OD)
Overall 9.4 (4.6-17.5) 57.9 (34.0-78.9) 52.9 (28.5-76.1)
Poly RF-positive 18.8 (5.0-46.3) 85.9 (77.1-91.8) 17.6 (4.6-44.2)
Poly RF-negative 5.6 (1.0-20.0) 70.9 (59.4-80.3) 11.8 (2.1-37.7)
Oligoarthritis 0 81.1 (71.2-88.3) 0
Systemic-Onset 7.7 (0.4-37.9) 84.3 (75.5-90.5) 5.9 (0.3-31.0)
IgG anti-CCP antibodies (> 20U)
Overall 14.6 (8.5-23.6) 94.7 (71.9-99.7) 93.3 (66.0-99.7)
Poly RF-positive 56.3 (30.6-79.2) 93.9 (86.8-97.5) 60.0 (32.9-82.5)
Poly RF-negative 13.9 (5.2-30.3) 87.3 (77.5-93.4) 33.3 (13.0-61.3)
Oligoarthritis 0 83.3 (73.7-90.0) 0
Systemic-Onset 0 85.3 (76.6-91.2) 0
IgA anti-CCP antibodies (> 0.16OD)
Overall 10.4 (5.4-18.7) 84.2 (59.5-95.8) 76.9 (46.0-93.8)
Poly RF-positive 25.0 (8.3-52.6) 90.9 (83.0-95.5) 30.8 (10.3-61.1)
Poly RF-negative 16.7 (6.9-33.5) 91.1 (82.0-96.1) 46.2 (20.4-73.9)
Oligoarthritis 0 85.6 (76.2-91.8) 0
Systemic-Onset 0 87.3 (78.8-92.8) 0
IgM Anti-CCP Antibodies (> 0.45OD)
Overall 16.7 (10.1-26.0) 73.7 (48.6-89.9) 76.2 (52.5-90.9)
Poly RF-positive 31.3 (12.1-58.5) 83.8 (74.8-90.2) 23.8 (9.1-47.5)
Poly RF-negative 16.7 (6.9-33.5) 91.1 (82.0-96.1) 46.2 (20.4-73.9)
Oligoarthritis 0 76.7 (66.3-84.7) 0
Systemic-Onset 7.7 (0.4-37.9) 80.4 (71.1-87.3) 4.8 (0.2-25.9)
IgA RF (> 6U)
Overall 15.6 (9.3-24.8) 84.2 (59.5-95.8) 83.3 (57.7-95.6)
Poly RF-positive 62.5 (35.9-83.7) 91.9 (84.2-96.2) 55.6 (31.3-77.6)
Poly RF-negative 11.1 (3.6-27.0) 82.2 (71.7-89.6) 22.2 (7.4-48.1)
Oligoarthritis 0 80.0 (70.0-87.4) 0
Systemic-Onset 7.7 (0.4-37.9) 83.3 (74.4-89.7) 5.6 (0.3-29.4)
IgM RF (> 6U)
Overall 47.9 (37.7-58.3) 63.1 (38.6-82.8) 86.8 (74.0-94.1)
Poly RF-positive 100.0 (75.9-100.0) 62.6 (52.3-72.0) 30.2 (18.7-44.5)
Poly RF-negative 47.2 (30.8-64.7) 54.4 (42.9-65.5) 32.1 (20.3-46.4)
Oligoarthritis 20.0 (7.6-41.3) 46.7 (36.2-57.4) 9.4 (3.5-21.4)
Systemic-Onset 61.5 (32.3-84.9) 55.9 (45.7-65.6) 15.1 (7.2-28.1)
Anti-CCP antibodies: anti-cyclic citrullinated peptide antibodies; OD: optical density; CI: confidence interval; PPV: positive predictive value; RF: rheumatoid factor;
U: units. Subtypes with small sample size were not included in the subtype analysis.
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when measuring IgM RF by ELISA, explaining an
increased prevalence of IgM RF in patients diagnosed
with IgM RF-negative polyarthritis, systemic-onset JIA,
and oligoarthritis. In addition, our JIA patients initially
diagnosed with systemic-onset JIA later developed dif-
fuse polyarticular disease and then IgM RF positivity on
several evaluations, originally being IgM RF negative by
nephelometry or latex agglutination.
IgG anti-CCP antibodies and IgM RF had the strongest
association with radiographic progression in JIA. Fifty
percent of JIA patients with joint damage demonstrated
increased reactivity to anti-citrullinated fibrinogen antibo-
dies; however, no statistical correlation was noted. A con-
clusion can be drawn that while anti-citrullinated
fibrinogen antibodies were prevalent in JIA, other pro-
teins may be citrullinated, and could possibly demon-
strate stronger association with joint damage. Further
evaluation of various target proteins, including vimentin
and type II collagen, are necessary to determine the sig-
nificance of this modification in JIA pathogenesis. These
studies are currently underway in our laboratory.
Conclusions
Of the antibodies measured in this study, anti-citrulli-
nated fibrinogen antibodies showed the strongest asso-
ciation with JIA when compared to healthy and SLE
control groups. Additionally, anti-citrullinated fibrinogen
antibodies demonstrated high sensitivity for IgM RF-
positive polyarthritis patients, along with anti-CCP anti-
body isotypes and IgM RF demonstrating high specifici-
ties. Our data would suggest that measuring anti-
citrullinated fibrinogen antibodies, in addition to anti-
CCP antibody isotypes and IgM RF, may be beneficial in
identifying patients that will develop more aggressive
disease. For the first time, we have identified fibrinogen
as a potential target for citrullination in JIA, particularly
in patients with IgM RF-positive polyarticular JIA.
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